OpiAID
PrivateLast Round
Angel
Feb 26, 2024
Total Funding Raised
$4.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
OpiAID operates in Healthcare & Life Sciences and is based in Wilmington, North Carolina. Its latest recorded funding round was an Angel round in February 2024.
OpiAID is a health technology company that provides a data science platform integrating electronic health records and biometric data from wearables to support clinicians in treating opioid use disorder.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Mental Health, Health IoT, EHR & EMR, Telemedicine
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OpiAID Comparables
Compare OpiAID with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Behaivior | 89% | |
| DynamiCare Health | 76% | |
| Kipu Health | 70% |
For institutional investors. Book with your work email.
OpiAID Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Angel | Feb 26, 2024 | ||||
| Seed | Jan 1, 2024 | ||||
| Grant | May 3, 2023 | ||||
| Grant | Nov 16, 2022 | ||||
| Grant | May 13, 2021 | ||||
Grant | Feb 2, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
OpiAID Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NC IDEA | Grant |
| National Institute on Drug Abuse | Grant |
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| North Carolina Biotechnology Center | Debt |
| One North Carolina Small Business Program | Grant |
| National Institute on Drug Abuse | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 77% MoM.
- May 3, 2023
Secured $3M from National Institute on Drug Abuse and NIH RADx.
For institutional investors. Book with your work email.
OpiAID Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about OpiAID's valuation, stock price, and market status.
Is OpiAID a public or private company?
OpiAID is a private company.
What is the current stock price of OpiAID?
OpiAID is a private company, so its shares have no public market price. Caplight tracks OpiAID's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OpiAID worth (valuation)?
Valuation information for OpiAID is not publicly available.
Can I buy OpiAID stock?
OpiAID shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OpiAID's last funding round?
OpiAID's most recent funding round was Angel on February 26, 2024.
Who are the main investors in OpiAID?
Key investors in OpiAID include NC IDEA, National Institute on Drug Abuse, U.S. Department of Health and Human Services, NIH RADx, North Carolina Biotechnology Center.
Will OpiAID IPO soon?
No public IPO plans have been announced for OpiAID.
How can I track OpiAID secondary market activity?
Caplight tracks bids, offers, and trades in OpiAID's shares on secondary markets.